Search

Sushma Kommareddy

from Hopkinton, MA
Age ~48
Get Report
Also known as:
Sushma Y
Related to:
Ravi Chandra Kollipara, 49Pavan Kumar Srirama, 43Rao R Kollipara, 79
Connected to:
Lanell F Kommatas, 58Lori A Kommedahl, 66Allison R Kommel, 59Kevin E Kommel, 38William R Kommel, 73Christine A Kommer, 81Erik Kommer, 33Gerald D Kommer, 65Krista Kommer, 45Valerie P Kommer, 36

Sushma Kommareddy Phones & Addresses

  • Hopkinton, MA
  • Waltham, MA
  • 128 Lowell St, Lexington, MA 02420
  • Dorchester, MA
  • Concord, NH
  • 66 Beach Point Pl APT 309, Dorchester, MA 02125

Work

Position: Installation, Maintenance, and Repair Occupations

Publications

Us Patents

Concentration Of Vaccine Antigens Without Lyophilization

View page
US Patent:
20130224245, Aug 29, 2013
Filed:
Jun 1, 2011
Appl. No.:
13/700436
Inventors:
Sushma Kommareddy - Waltham MA, US
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Laxington MA, US
Barbara Baudner - Siena, IT
Assignee:
Novartis AG - Basel
International Classification:
A61K 39/145
US Classification:
4242101
Abstract:
An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating a vaccine from the concentrated antigen. The concentrated antigen is not lyophilised between or during steps (i) and (ii). The invention is particularly useful for preparing solid vaccine forms.

Concentration Of Vaccine Antigens With Lyophilization

View page
US Patent:
20130243841, Sep 19, 2013
Filed:
Jun 1, 2011
Appl. No.:
13/700437
Inventors:
Sushma Kommareddy - Waltham MA, US
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Cary NC, US
Amanda Scampini Bonificio - Cambridge MA, US
Barbara Baudner - Siena, IT
Assignee:
Novartis AG - Basel
International Classification:
A61K 9/00
US Classification:
424422, 4241841, 4242341, 4242041, 4242741, 4242651, 4242091, 424443
Abstract:
A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens.

Benzonaphthyridine-Containing Vaccines

View page
US Patent:
20120263753, Oct 18, 2012
Filed:
Jun 10, 2010
Appl. No.:
13/377511
Inventors:
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Lexington MA, US
Siddhartha Jain - Cambridge MA, US
Sushma Kommareddy - Waltham MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 39/39
A61P 37/04
A61K 39/02
A61K 39/00
A61K 39/12
US Classification:
4242041, 4242801, 4242771, 4242341, 4242741, 4242651
Abstract:
The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.

Inactivated Virus Compositions And Zika Vaccine Formulations

View page
US Patent:
20220211836, Jul 7, 2022
Filed:
Apr 8, 2020
Appl. No.:
17/609217
Inventors:
- Cambridge MA, US
Sushma KOMMAREDDY - Cambridge MA, US
Assignee:
Takeda Vaccines, Inc. - Cambridge MA
International Classification:
A61K 39/12
A61K 47/10
A61K 47/26
A61K 47/02
Abstract:
The present invention relates to a liquid inactivated virus composition comprising: an inactivated whole Zika virus, at least one pharmaceutically acceptable buffer with a concentration of at least about 6.5 mM, and optionally a polyol, wherein said at least one pharmaceutically acceptable buffer does not comprise phosphate ions and vaccines derived therefrom.
Control profile
Sushma Kommareddy from Hopkinton, MA, age ~48 Get Report